SCHEMBL5158586

SCHEMBL5158586

O=C(CC(=O)N1CCCC1)c1ccncc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLOD2 O00469 4/20 0.53
PLOD3 O60568 4/20 0.53
PLOD1 Q02809 4/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP2C9 P11712 1/20 0.53
HIF1A Q16665 1/20 0.53
KDM4E B2RXH2 2/20 0.51
GLA P06280 1/20 0.51
TSHR P16473 1/20 0.51
RAB9A P51151 1/20 0.51
NAMPT P43490 2/20 0.47
RECQL P46063 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160900 0.98 PLOD2 (0.51) PLOD2PLOD3PLOD1ALDH1A1HPGD
SCHEMBL12904337 0.85 PLOD2 (0.58) PLOD2PLOD3PLOD1ALDH1A1HPGD
SCHEMBL5160465 0.81 PLOD2 (0.59) PLOD2PLOD3PLOD1ALDH1A1RAB9A
SCHEMBL6692694 0.81 HPGD (0.59) ALDH1A1HPGDCYP1A2CYP3A4CYP2C19
SCHEMBL5160487 0.80 PLOD2 (0.58) PLOD2PLOD3PLOD1ALDH1A1KDM4E
SCHEMBL5163185 0.79 VNN1 (0.47) ALDH1A1HPGDRAB9AL3MBTL1CHRM2
SCHEMBL5160072 0.78 VNN1 (0.49) ALDH1A1HPGDTSHRRAB9ASMN1; SMN2
SCHEMBL5163142 0.78 P2RX7 (0.49) HPGDMAPK1SMN1; SMN2L3MBTL1CHRM2
SCHEMBL12490113 0.77 HPGD (0.72) ALDH1A1HPGDCYP3A4CYP2C19CYP2C9
SCHEMBL10948430 0.77 PLOD2 (0.83) PLOD2PLOD3PLOD1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO PLOD2 1169/4885PLOD3 3951/4885PLOD1 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.